Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
ALS (motor neurone disease)
FollowWhat is new in ALS (motor neurone disease) research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- Debamestrocel - MSC-NTF (NurOwn)Phase 3 · NCT06973629
- Masitinib (4.5)Phase 3 · NCT03127267
- Masitinib (6.0)Phase 3 · NCT03127267
- Masitinib 4.5 mg/kg/dayPhase 3 · NCT07174492
- PridopidinePhase 3 · NCT07322003 · NCT04297683
- RiluzolePhase 3 · NCT03127267
- Riluzole (100 mg)Phase 3 · NCT07142291 · NCT07174492
- TofersenPhase 3 · NCT04856982 · NCT07294144
- ABBV-CLS-7262Phase 2/3 · NCT04297683
- Acetyl-l-carnitinePhase 2/3 · NCT06126315
- Amantadine Hydrochloride Oral SolutionPhase 2/3 · NCT04302870
- CNM-Au8Phase 2/3 · NCT04297683
- COYA 302Phase 2/3 · NCT07161999
- DNL343Phase 2/3 · NCT04297683
- Galunisertib + Nerandomilast CombinationPhase 2/3 · NCT07321860
- Matching placeboPhase 2/3 · NCT07410806
- Memantine Hydrochloride Oral SolutionPhase 2/3 · NCT04302870
- MN-166Phase 2/3 · NCT04057898
- NUZ-001Phase 2/3 · NCT07410806 · NCT04297683
- RAPA-501 Autologous T stem cellsPhase 2/3 · NCT04220190
- SLS-005 TrehalosePhase 2/3 · NCT04297683
- Tacrolimus 1Mg CapPhase 2/3 · NCT04302870
- TazbentetolPhase 2/3 · NCT07325591
- Test drug CB03-154 10mg groupPhase 2/3 · NCT07082192
- Test drug CB03-154 15mg groupPhase 2/3 · NCT07082192
- Test drug CB03-154 5mg groupPhase 2/3 · NCT07082192
- Trazodone Hydrochloride oral solutionPhase 2/3 · NCT04302870
- VerdiperstatPhase 2/3 · NCT04297683
- ZilucoplanPhase 2/3 · NCT04297683
- 50 mg UsnoflastPhase 2 · NCT07023835
- 75 mg UsnoflastPhase 2 · NCT07023835
- AntioxidantsPhase 2 · NCT04244630
- Autologous Adipose-derived Mesenchymal Stromal CellsPhase 2 · NCT03268603
- C. cicadaePhase 2 · NCT07467746
- CNMAu8Phase 2 · NCT05299658
- ControlPhase 2 · NCT07467746
- Cromolyn Sodium (17.1 mg BID)Phase 2 · NCT07142291
- Cromolyn Sodium (34.2 mg BID)Phase 2 · NCT07142291
- Darifenacin 7.5 MG Extended Release Oral TabletPhase 2 · NCT06249867
- FHND1002 100mgPhase 2 · NCT07138014
- FHND1002 200mgPhase 2 · NCT07138014
- Foralumab NasalPhase 2 · NCT07688239
- MetforminPhase 2 · NCT04220021
- Non-invasive ventilationPhase 2 · NCT07071935
- NX210cPhase 2 · NCT06365216
- Psilocybin therapyPhase 2 · NCT06782724
- RanolazinePhase 2 · NCT06527222
- 18F-OP-801Phase 1/2 · NCT05395624
- BIIB147Phase 1/2 · NCT07855211
- KamlanoflastPhase 1/2 · NCT07396818
- MTP-101CPhase 1/2 · NCT07017946
- nL-CHCHD-001Phase 1/2 · NCT07095686 · NCT07423494 · NCT06977451 · NCT06392126
- nL-TARDB-002Phase 1/2 · NCT07703462
- nL-TARDB-006Phase 1/2 · NCT07743268
- PLL001 or placebo daily subcutaneous injectionsPhase 1/2 · NCT06513546
- Preventative (Prophylactic) Medication - Corticosteroids: MethylprednisolonePhase 1/2 · NCT07287397
- SNUG01Phase 1/2 · NCT07169175 · NCT06645197
- TRCN-1023Phase 1/2 · NCT07674667
- VTx-002Phase 1/2 · NCT07287397
- AAV9 Gene therapyPhase 1 · NCT07401121
- AmisodinPhase 1 · NCT07221240
- AMX0114Phase 1 · NCT06665165
- B cell infusionPhase 1 · NCT07838389
- CNS10-NPC-GDNFPhase 1 · NCT05306457
- Definity® Vial for (Perflutren Lipid Microsphere) Injectable SuspensionPhase 1 · NCT07193953
- Intravenous immunoglobulin (IVIG), 10% solution for infusionPhase 1 · NCT07193953
- LY4256984Phase 1 · NCT07100119
- Multiple ascending doses of PlaceboPhase 1 · NCT05633459
- Multiple ascending doses of QRL-201Phase 1 · NCT05633459
- Next Generation Dome Helmet Focused UltrasoundPhase 1 · NCT07193953
- NTF001 InjectionPhase 1 · NCT07618585
- prosetinPhase 1 · NCT05279755
- QRL-201Phase 1 · NCT05633459
- XT-150Phase 1 · NCT06704347
- β-hydroxy-β-methylbutyrate (HMB)Phase 1 · NCT07589764
- A sterile aqueous solution of RAG - 17 preparation (sodium salt)Early phase 1 · NCT07077668
- RJK002 Intrathecal injectionEarly phase 1 · NCT06454682
- The study drug is SHED-CM manufactured by U-FactorEarly phase 1 · NCT06889857
- VGN-R13Early phase 1 · NCT06849609
Closest to patients
- Study of COYA 302 for the Treatment of ALSStudy of COYA 302 for the Treatment of ALSUniversity of British Columbia · Vancouver, Canada + 24 more hospitalsPhase 2/3Results expected 2027
- Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSMediciNova (sponsor) · 16 hospitals in United States and CanadaPhase 2/3Results expected 2027
- Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALSTrial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALSAOU di Modena Nuovo Ospedale Civile S. Agostino Estense di Modena - Ospedale di Baggiovara · Modena, Italy + 19 more hospitalsPhase 2/3Results expected 2027
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Combined melatonin and edaravone therapy attenuates methylmercury-induced amyotrophic lateral sclerosis-like neurodegeneration through GLP-1 modulation and myelin preservation.
Combined melatonin and edaravone therapy attenuates methylmercury-induced amyotrophic lateral sclerosis-like neurodegeneration through GLP-1 modulation and myelin preservation.
Naunyn-Schmiedeberg's archives of pharmacology
PubMed · PMID 42946847Publication
Salivary Dim-Light Melatonin Onset is Associated with Functional Decline, Respiratory Symptom Emergence, and Survival in Early Amyotrophic Lateral Sclerosis.
Salivary Dim-Light Melatonin Onset is Associated with Functional Decline, Respiratory Symptom Emergence, and Survival in Early Amyotrophic Lateral Sclerosis.
Annals of neurology
PubMed · PMID 42885660Publication
Combined rituximab and magnesium acetyl taurate therapy attenuates neurodegeneration via ERK/c-JNK/P38MAPK signaling modulation in methylmercury-induced amyotrophic lateral sclerosis-like neurotoxicity.
Combined rituximab and magnesium acetyl taurate therapy attenuates neurodegeneration via ERK/c-JNK/P38MAPK signaling modulation in methylmercury-induced amyotrophic lateral sclerosis-like neurotoxicity.
Naunyn-Schmiedeberg's archives of pharmacology
PubMed · PMID 42864501
Find fellow researchers
Groups with active ALS (motor neurone disease) work.
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
King's College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Massachusetts General Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Sheffield
Sheffield, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Centre National de la Recherche Scientifique
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
University Medical Center Utrecht
Utrecht, Netherlands
Team details appear once the team leader joins.
Is this your team? Claim it
German Center for Neurodegenerative Diseases
Bonn, Germany
Team details appear once the team leader joins.
Is this your team? Claim it
UCL Queen Square Institute of Neurology
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
University of Oxford
Oxford, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it